Fig 1.tif (1.06 MB)

Tissue expression patterns of LYZL6.

Download (1.06 MB)
posted on 09.02.2017, 18:36 by Peng Huang, Wenshu Li, Zhifang Yang, Ning Zhang, Yixin Xu, Jianying Bao, Deke Jiang, Xianping Dong

A) RT–PCR analysis. Lane M: DL2000 DNA marker. The expected sizes of PCR products were 296 bp for LYZL6 and 247 bp for G3PDH. Totally 14 tissues were examined. Nine of them were shown and the rest included the pancreas, small intestine, colon, thymus and skeletal muscle. B) Anti-LYZL6 serum specificity analysis. Top panel: SDS-PAGE; Bottom panel: western blotting. Lane M: molecular weight (MW) marker; The expected MW was ~14.7 kDa for LYZ and ~32.0 kDa for His-tagged LYZL6 (HLYZL6) and His-tagged LYZL4 (HLYZL4), which the extra MW resulted from Trx-tag, S-tag and restriction enzyme site of the pET32a vector. The amount of His-tagged LYZL6 and His-tagged LYZL4 loaded was 0.5 μg and that of LYZ was 0.1 μg. C) Western blot analysis of human tissue extracts. A band corresponding to full-length LYZL6 was evident in the testis and epididymis. No expression was detected in the other human tissues. D) Western blot analysis of LYZL6 in human semen. LYZL6 was identified in protein lysates representing different numbers of ejaculated spermatozoa (left), but not in seminal plasma (right). β-actin and LYZ were used as internal controls respectively.